FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Received approval for a Phase 1 trial of its intestinal organoid therapy in Crohn's disease and runs a GMP center in Gwangmyeong.

  • Announced approval of a Phase 1 trial of ATORM-C in Crohn's disease. Source

Roles often seen at this stageClinical & PV · Research & development · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

OrganoidSciences

Develops regenerative therapies and drug-efficacy testing solutions based on organoids grown from stem cells in 3D culture; listed on KOSDAQ in May 2025.

ATORM-C

Phase 1

Intestinal organoid therapy derived from the patient's own adult stem cells; received MFDS approval in March 2026 for a Phase 1 trial in Crohn's disease with colonic ulcers.

ODISEI

Marketed

Organoid-based efficacy testing solution for new materials, first commercialized in Korea in 2020.

Gwangmyeong GMP Center

Service

GMP center of about 250 pyeong at SK Techno Park in Gwangmyeong, licensed for manufacturing and cell processing in Q4 2022.

Completion reported

Received approval for a Phase 1 trial of ATORM-C in Crohn's disease, enrolling 9 to 18 patients at Asan Medical Center in Seoul.

Completion reported

Listed on KOSDAQ through the technology special listing route, raising about 25.2 billion won.

Official role guide

OrganoidSciences careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 4

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. About Us ↗오가노이드사이언스 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  2. '차세대 재생 치료제' 오가노이드사이언스, 코스닥 데뷔[오늘 상장] ↗이데일리 · Published 2025-05-09 · Sources checked 2026-11-18 · Original unavailable
  3. "장 오가노이드로 크론병 치료"…오가노이드사이언스 임상 1상 진입 ↗유니콘팩토리 · Published 2026-03-16 · Sources checked 2026-11-18 · Original unavailable
  4. Careers ↗오가노이드사이언스 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable